Decoy Therapeutics
DCOY
5 hedge funds and large institutions have $637K invested in Decoy Therapeutics in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
20% more capital invested
Capital invested by funds: $532K → $637K (+$105K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$155K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$37.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
DCOY Hedge Fund Activity: Q2 2020 in Review
5 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2020, worth a combined $637K — up 20% from $532K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DCOY and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $155K sold.
- 5 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2020, down from 6 in Q1 2020.
- Funds reported $637K of Decoy Therapeutics stock for Q2 2020, up 20% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q2 2020 and 1 closed out, a net change of -1 holder.
- The largest Decoy Therapeutics seller in Q2 2020 was Renaissance Technologies, an estimated $155K sold.
Based on aggregated 13F filings for Q2 2020.